Detection of Reductions in Cystic Fibrosis Airway Inflammation While Using Aztreonam Lysine Solution
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
In cystic fibrosis, there is a critical need for better predictors of treatment response. The investigators have identified a panel of white blood cell biomarkers which can be directly measured as a blood test in subjects with cystic fibrosis. These biomarkers predict reduction of airway inflammation and infection more accurately than lung function testing, in patients receiving intravenous antibiotic therapy. In the current study, we hypothesize that this panel of gene biomarkers which can be readily measured from peripheral blood will sensitively predict changes in inflammation when patients receive inhaled antibiotic therapy, specifically Cayston (or inhaled aztreonam lysine). Patients enrolled in the study will have blood drawn before and after a month of inhaled Cayston, in order to test whether genes predict response to Cayston therapy more robustly than do standard measures such as lung function tests.
Condition or disease
Cystic Fibrosis in Adults, Chronic Colonization With Pseudomonas Aeruginosa
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 75 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Enrolled subjects will include adults with cystic fibrosis, over the age of 18 years, who are at baseline health and colonized with Pseudomonas aeruginosa, and who are newly prescribed Cayston (aztreonam lysine) for inhalation, or who are resuming use of this drug after 28 days off of inhaled antimicrobial agents with activity against Pseudomonas aeruginosa.
Documented diagnosis of cystic fibrosis
Age 18 years old or greater
FEV1 percent predicted greater than 25%
Ability to perform reproducible pulmonary function tests and produce sputum spontaneously
Chronic bacterial colonization with Pseudomonas aeruginosa with 2 positive cultures in previous 2 years.
Chronically stable pulmonary condition without evidence of acute pulmonary exacerbation within 14 days prior to screening
Starting Cayston cycle as part of clinical care.
Presence of a condition or abnormality that, in the opinion of the Principal Investigator (PI), would compromise the safety of the patient or the quality of the data.
Aztreonam allergy, bronchospasm or other contraindication to use of aztreonam.
Signs and symptoms of acute pulmonary exacerbation at the time of enrollment or during study.
Active infection and treatment for non-tuberculous mycobacteria.
Concomitant use of systemic steroids.
Use of inhaled antimicrobial agents with activity against Pseudomonas aeruginosa within 28 days prior to Visit 1.